Evogene Ltd. (NASDAQ:EVGN) Shares Shorted: Short Interest Up 1,541.9% in September

Evogene Ltd. (NASDAQ:EVGN) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 932,725 shares, a growth of 1,541.9% from the September 15th total of 56,809 shares. Currently, 11.6% of the company’s shares are short sold. Based on an average daily volume of 6,278,931 shares, the days-to-cover ratio is presently 0.1 days.

Insider Activity

In other Evogene news, Director Leon Recanati bought 460,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares in the company, valued at approximately $860,087.04. This trade represents a 52.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Evogene Trading Down 4.1%

NASDAQ EVGN traded down $0.02 on Friday, hitting $0.38. 105,888 shares of the company were exchanged, compared to its average volume of 1,171,209. The company has a market cap of $3.33 million, a PE ratio of -0.42 and a beta of 1.44. The stock has a fifty day moving average of $0.52 and a 200-day moving average of $0.61. Evogene has a 12 month low of $0.35 and a 12 month high of $1.49.

About Evogene

Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.

Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.